MOLOGNI LUCA

Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Detail

Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Detail

Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail

Aroldi, A., Mauri, M., Ramazzotti, D., Villa, M., Malighetti, F., Crippa, V., et al. (2023). Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 27(20 (October 2023)), 3053-3064 [10.1111/jcmm.17868]. Detail

Malighetti, F., Arosio, G., Manfroni, C., Mauri, M., Villa, M., Manghisi, B., et al. (2023). DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients. HEMASPHERE, 7(3) [10.1097/HS9.0000000000000852]. Detail